Idiopathic Pulmonary Fibrosis Market - By Drug Type: [Antifibrotic Agents, Immunosuppressants, Tyrosine Kinase Inhibitors, Others], By Mode of Action: [Anti-inflammatory, Antifibrotic, Others], By End User: [Hospitals, Specialty Clinics, Others], Regional Analysis: [North America (U.S., Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Rest of Asia Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East & Africa)].
| 1. Global Idiopathic Pulmonary Fibrosis Market Research Report |
| 1.1. Study Objectives |
| 1.2. Idiopathic Pulmonary Fibrosis Market – Overview |
| 1.3. Reasons to Read This Report |
| 1.4. Methodology and Forecast Analysis |
| 2. Global Idiopathic Pulmonary Fibrosis Market Research Report - Preface |
| 2.1. Global Idiopathic Pulmonary Fibrosis Market Research Report – Detailed Scope and Definitions |
| 2.1.1. By Drug Type |
| 2.1.2. By Mode of Action |
| 2.1.3. By End User |
| 2.1.4. By Region |
| 3. Global Idiopathic Pulmonary Fibrosis Market Dynamics |
| 3.1. Drivers - Macro-Economic Based, Supply Side, and Demand Side Drivers |
| 3.2. Restraints – By Drug Type, By Mode of Action, By End User, By Country |
| 3.3. Opportunities – By Drug Type, By Mode of Action, By End User, By Country |
| 3.4. Trends – By Drug Type, By Mode of Action, By End User, By Country |
| 3.5. PEST Analysis |
| 3.6. Porters Five Rule Analysis |
| 3.7. Company’s Share Analysis (CSA) by Region or By Country |
| 3.8. Global Idiopathic Pulmonary Fibrosis Market Research Report – DROTs Impact Analysis |
| 4. Global Idiopathic Pulmonary Fibrosis Market Research Report, Historic Data 2019 - 2023 and Forecast Analysis Data 2024 - 2031 |
| 4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 4.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 4.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and 2024 to 2031 |
| 4.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 5. Global Idiopathic Pulmonary Fibrosis Market, By Drug Type, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn) |
| 5.1. Nintedanib |
| 5.1.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 5.1.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 5.1.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 5.1.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 5.2. Pirfenidone |
| 5.2.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 5.2.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 5.2.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 5.2.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 5.3. Others |
| 5.3.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 5.3.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 5.3.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 5.3.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 6. Global Idiopathic Pulmonary Fibrosis Market, By Mode of Action, 2019 - 2023 and Forecast, 2024 - 2029 (Market Value, In USD Mn) |
| 6.1. Antifibrotic Agents |
| 6.1.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 6.1.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 6.1.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 6.1.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 6.2. Tyrosine Kinase Inhibitors |
| 6.2.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 6.2.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 6.2.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 6.2.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 6.3. Other Modes of Action |
| 6.3.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 6.3.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 6.3.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 6.3.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 7. Global Idiopathic Pulmonary Fibrosis Market, By End User, 2019 - 2023 and Forecast, 2024 - 2029 (Market Value, In USD Mn) |
| 7.1. Hospitals and Clinics |
| 7.1.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 7.1.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 7.1.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 7.1.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 7.2. Pharmacies |
| 7.2.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 7.2.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 7.2.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 7.2.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 7.3. Others |
| 7.3.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 7.3.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 7.3.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 7.3.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 8. Global Idiopathic Pulmonary Fibrosis Market Forecast, By Region, 2019 - 2023 and Forecast, 2021 – 2027 (Market Value, In USD Mn ) |
| 8.1. North America |
| 8.1.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 8.1.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 8.1.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 8.1.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 8.2. Europe |
| 8.2.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 8.2.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 8.2.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 8.2.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 8.3. Asia-Pacific |
| 8.3.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 8.3.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 8.3.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 8.3.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 8.4. Latin America |
| 8.4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 8.4.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 8.4.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 8.4.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 8.5. Middle East and Africa |
| 8.5.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 – 2031 Trends (USD Millions) |
| 8.5.2. Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%). |
| 8.5.3. Incremental Market Value/Volume Opportunity between 2019 – 2023 and From 2024 to 2031 |
| 8.5.4. Market Shares Analysis in Years - 2019, 2023, 2026 and 2031 |
| 8.6. Global Idiopathic Pulmonary Fibrosis Market - Opportunity Analysis Index, By Drug Type, By Mode of Action, By End User, and Region, 2024 - 2031 |
| 9. North America Idiopathic Pulmonary Fibrosis Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn) |
| 9.1. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 9.1.1. Nintedanib |
| 9.1.2. Pirfenidone |
| 9.1.3. Other Drug Types |
| 9.2. Mode of Action Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 9.2.1. Antifibrotic Agents |
| 9.2.2. Tyrosine Kinase Inhibitors |
| 9.2.3. Others |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 9.3.1. Hospitals & Clinics |
| 9.3.2. Pharmacies |
| 9.3.3. Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 9.4.1. U.S. |
| 9.4.2. Canada |
| 9.5. North America Idiopathic Pulmonary Fibrosis Market – Opportunity Analysis Index, By Drug Type, By Mode of Action, By End User, and Country, 2024 - 2031 |
| 9.6. Reginal Trends Analysis |
| 9.7. North America Idiopathic Pulmonary Fibrosis Market Research Report - Company Profiles |
| 9.7.1. Company 1 (USA) |
| 9.7.2. Company 2 (USA) |
| 9.7.3. Company 3 (Canada) |
| 10. Europe Idiopathic Pulmonary Fibrosis Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn ) |
| 10.1. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 10.1.1. Nintedanib |
| 10.1.2. Pirfenidone |
| 10.1.3. Other Drug Types |
| 10.2. Mode of Action Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 10.2.1. Antifibrotic Agents |
| 10.2.2. Tyrosine Kinase Inhibitors |
| 10.2.3. Others |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 10.3.1. Hospitals & Clinics |
| 10.3.2. Pharmacies |
| 10.3.3. Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Poland |
| 10.4.8. Rest of Europe |
| 10.5. Europe Idiopathic Pulmonary Fibrosis Market – Opportunity Analysis Index, By Drug Type, By Mode of Action, By End User, and Country, 2024 - 2031 |
| 10.6. Reginal Trends Analysis |
| 10.7. Europe Idiopathic Pulmonary Fibrosis Market Research Report - Company Profiles |
| 10.7.1. Company – 1 (Germany) |
| 10.7.2. Company – 2 (U.K) |
| 10.7.3. Company – 3 (France) |
| 11. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Analysis, 2019 – 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn ) |
| 11.1. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 11.1.1. Nintedanib |
| 11.1.2. Pirfenidone |
| 11.1.3. Other Drug Types |
| 11.2. Mode of Action Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 11.2.1. Antifibrotic Agents |
| 11.2.2. Tyrosine Kinase Inhibitors |
| 11.2.3. Others |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 11.3.1. Hospitals & Clinics |
| 11.3.2. Pharmacies |
| 11.3.3. Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Idiopathic Pulmonary Fibrosis Market – Opportunity Analysis Index, By Drug Type, By Mode of Action, By End User, and Country, 2024 - 2031 |
| 11.6. Regional Trends Analysis |
| 11.7. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Research Report - Company Profiles |
| 11.7.1. Company – 1 (China) |
| 11.7.2. Company – 2 (India) |
| 11.7.3. Company – 3 (Japan) |
| 12. Latin America Idiopathic Pulmonary Fibrosis Market Analysis, 2019 - 20223 and Forecast, 2024 – 2031 |
| 12.1. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 12.1.1. Nintedanib |
| 12.1.2. Pirfenidone |
| 12.1.3. Other Drug Types |
| 12.2. Mode of Action Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 12.2.1. Antifibrotic Agents |
| 12.2.2. Tyrosine Kinase Inhibitors |
| 12.2.3. Others |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 12.3.1. Hospitals & Clinics |
| 12.3.2. Pharmacies |
| 12.3.3. Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2021 – 2027 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Idiopathic Pulmonary Fibrosis Market – Opportunity Analysis Index, By Drug Type, By Mode of Action, By End User, and Country, 2024 - 2031 |
| 12.6. Regional Trends Analysis |
| 12.7. Latin America Idiopathic Pulmonary Fibrosis Market Research Report - Company Profiles |
| 12.7.1. Company – 1 (Brazil) |
| 13. Middle East and Africa Idiopathic Pulmonary Fibrosis Market Analysis, 2019 - 2023 and Forecast, 2024 – 2031 (Revenue, USD Mn ) |
| 13.1. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 13.1.1. Nintedanib |
| 13.1.2. Pirfenidone |
| 13.1.3. Other Drug Types |
| 13.2. Mode of Action Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 13.2.1. Antifibrotic Agents |
| 13.2.2. Tyrosine Kinase Inhibitors |
| 13.2.3. Others |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 13.3.1. Hospitals & Clinics |
| 13.3.2. Pharmacies |
| 13.3.3. Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Idiopathic Pulmonary Fibrosis Market - Opportunity Analysis Index, By Drug Type, By Mode of Action, By End User, and Country, 2024 - 2031 |
| 13.6. Regional Trends Analysis |
| 13.7. MEA Idiopathic Pulmonary Fibrosis Market Research Report - Company Profiles |
| 13.7.1. Company – 1 (GCC) |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis) |
| 14.2.1. United Therapeutics Corporation |
| 14.2.2. Boehringer Ingelheim International GmbH |
| 14.2.3. Bristol-Myers Squibb Company |
| 14.2.4. Cipla Inc. |
| 14.2.5. F. Hoffmann-La Roche Ltd |
| 14.2.6. FibroGen Inc. |
| 14.2.7. MediciNova Inc. |
| 14.2.8. Jubliant Pharma Limited |
| 14.2.9. Merck & Co. Inc. |
| 14.2.10. Horizon Therapeutics Inc. |
| 14.2.11. Avalyn Pharma Inc. |
| 14.2.12. CS Pharmaceuticals |
| 14.2.13. Others |
| 15. Data Collection Method and Research Approach |
| 16. Principal Presumptions and Acronyms |
Need help?
Chat with our team in a minute.